Eikon Therapeutics Inc banner
E

Eikon Therapeutics Inc
NASDAQ:EIKN

Watchlist Manager
Eikon Therapeutics Inc
NASDAQ:EIKN
Watchlist
Price: 8.78 USD -6.99% Market Closed
Market Cap: $475m

Wall Street
Price Targets

EIKN Price Targets Summary
Eikon Therapeutics Inc

Wall Street analysts forecast EIKN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EIKN is 22.78 USD with a low forecast of 7.07 USD and a high forecast of 35.7 USD.

Lowest
Price Target
7.07 USD
19% Downside
Average
Price Target
22.78 USD
159% Upside
Highest
Price Target
35.7 USD
307% Upside
Eikon Therapeutics Inc Competitors:
Price Targets
CDNA
CareDx Inc
45% Upside
ARDX
Ardelyx Inc
172% Upside
ACIU
AC Immune SA
195% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Revenue forecast
is not available for
Eikon Therapeutics Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Eikon Therapeutics Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Net Income forecast
is not available for
Eikon Therapeutics Inc
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EIKN's stock price target?
Price Target
22.78 USD

According to Wall Street analysts, the average 1-year price target for EIKN is 22.78 USD with a low forecast of 7.07 USD and a high forecast of 35.7 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett